TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32090788
Drug: Rhodiola capsule
Normalized name: RHODIOLA ROSEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhodiola capsule (0.3 g/day) combined with sertraline
Study: 32090788
Drug: Sertraline with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline with two placebos (0.6 g/day)
Study: 33653757
Drug: Oral high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral high-dose vitamin D supplementation (50,000 IU cholecalciferol) taken monthly for 2 years, with an initial loading dose of 500,000 IU cholecalciferol.
Study: 35025149
Drug: Acupuncture (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (specific details on dosage and duration are not available)
Study: 34959924
Drug: Spinach extract
Normalized name: spinach extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinach extract supplementation (4 × 500 mg capsules/day; total 2 g per day) combined with moderate-intensity training (1 h session/3 times a week)
Study: 32196623
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg aspirin
Study: 36414575
Drug: Lipid-based nutritional
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutritional supplement (LNS)
Study: 35283411
Drug: Dual group
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual group (aspirin plus cilostazol)
Study: 35332289
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab therapy
Study: 34275830
Drug: Propofol dosing
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol dosing based on total body weight (TBW)
Study: 32044943
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (vancomycin or daptomycin + antistaphylococcal β-lactam)
Study: 32044943
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (vancomycin or daptomycin alone)
Study: 32044943
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (excluding dialysis patients)
Study: 32044943
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (excluding dialysis patients)
Study: 32815921
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg daily for 12 weeks
Study: 616120383
Drug: Anti-VEGF injections
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-VEGF injections
Study: 33858718
Drug: MMRV (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMRV (two doses)
Study: 33858718
Drug: MMR +
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR + V (one dose of MMR followed by one dose of V)
Study: 33858718
Drug: MMR (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR (control group, two doses)
Study: 33803814
Drug: HAplus gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAplus gel (Aminogam gel®) applied to gingival tissue post-extraction
Study: 33803814
Drug: HAplus gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAplus gel enriched with vitamins C and E (TEST groups)
Study: 32144829
Drug: Preoperative pelvic
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative pelvic floor muscle training (PFMT) daily from inclusion to surgery (n=81)
Study: 35578230
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (maximum of 6 sessions within 6 weeks, including spinal manipulation/mobilization, massage, and stretching)
Study: 33629490
Drug: Haemoglobin levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemoglobin levels of 70-89 g/l at 6+0 - 13+6 weeks
Study: 36482258
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg NMN
Study: 36482258
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg NMN
Study: 36482258
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg NMN
Study: 36482258
Drug: NMN (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: NMN (all doses)
Study: 36482258
Drug: HOMA-IR (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOMA-IR (all NMN doses)
Study: 33772133
Drug: PRP +
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP + CaCl2 solution
Study: 34222540
Drug: Benson's relaxation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benson's relaxation technique (listened to a voice containing relaxation technique twice a day for eight weeks)
Study: 33515539
Drug: Ceritinib +
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ceritinib + AKT inhibitors (Capivasertib and Afuresertib)
Study: 33515539
Drug: AKT inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKT inhibitors (Capivasertib and Afuresertib) alone
Study: 33121605
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis (AP) prescribing for invasive dental procedures in high-risk patients
Study: 33121605
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis (AP) prescribing for invasive dental procedures in moderate-risk patients
Study: 33121605
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis (AP) prescribing for invasive dental procedures in low or unknown risk patients
Study: 36087590
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg orally every 12 h for 7 days followed by 4 mg orally every 12 h for 7 days
Study: 32479903
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy (aPDT) with chloro-aluminum phthalocyanine (AlClPc) and scaling and root planning (SRP)
Study: 35611518
Drug: Three times
Normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three times weekly heparin flushing
Study: 35611518
Drug: Daily heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily heparin flushing (standard of care)
Study: 34459774
Drug: Daily infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily infusion volume
Study: 34559129
Drug: Zhen Wu
Normalized name: Ci Wu Jia
DrugBank: Eleuthero (DB14303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhen Wu Decoction (ZWD) with guideline directed medical therapies
Study: 34559129
Drug: ZWD-granules simulations
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ZWD-granules simulations with guideline directed medical therapies
Study: 35413644
Drug: Huangkui capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huangkui capsule (HKC) 2.5 g, TID
Study: 35413644
Drug: Zicuiyin decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zicuiyin decoction (ZCY) crude drug amount 75 g, 150 ml, BID
Study: 32709230
Drug: Real-time monitoring
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Real-time monitoring and just-in-time SMS medication reminders
Study: 32709230
Drug: Generic weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic weekly SMS reminders
Study: 32467417
Drug: GSK2862277 (26
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2862277 (26 mg nebulised dose)
Study: 32740347
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitor (ACEi) and/or angiotensin II receptor blocker (ARB)
Study: 36442902
Drug: Home-based multidisciplinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based multidisciplinary interventions (intensive stage for 6 weeks and maintenance stage for 6 weeks) including health education, follow-up, behaviour guide, social support, skill training, coping with adverse drug reactions, and problem-solving.
Study: 34298035
Drug: IM trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM trivalent inactivated influenza vaccine
Study: 34298035
Drug: imi+IM (IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: imi+IM (IM vaccine after topical imiquimod)
Study: 34298035
Drug: imi+ID (ID
Approvals — FDA: no, EMA: no, PMDA: no
Description: imi+ID (ID vaccine after topical imiquimod)
Study: 35845031
Drug: Aggressive lactated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive lactated Ringer's (LR) infusion
Study: 35845031
Drug: Aggressive normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive normal saline (NS) infusion
Study: 33620419
Drug: GDC‐0334 (TRPA1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDC‐0334 (TRPA1 antagonist)
Study: 32072735
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg/day plus saxagliptin 5 mg/day plus metformin
Study: 35742280
Drug: Square-stepping exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Square-stepping exercise (SSE) program, performed for 70 min per session, twice a week, for 12 weeks
Study: 36088952
Drug: Oral amoxicillin–clavulanic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin–clavulanic acid (75 mg/kg amoxicillin plus 18.75 mg/kg clavulanic acid, given daily in three doses for 7 days)
Study: 36088952
Drug: Oral amoxicillin–clavulanic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin–clavulanic acid
Study: 34873188
Drug: Cost compensation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost compensation (CC)
Study: 33248603
Drug: 0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg/kg natural ASTA
Study: 33248603
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg natural ASTA
Study: 33248603
Drug: 40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg natural ASTA
Study: 33248603
Drug: 80 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/kg natural ASTA
Study: 33248603
Drug: 160 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg/kg natural ASTA
Study: 36226385
Drug: Education intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Education intervention (verbal explanation and demonstration of inhaler technique with metered-dose inhaler using a mannequin)
Study: 35675658
Drug: 8-Week Self-administered
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-Week Self-administered Home-Based Virtual Reality Program
Study: 32443695
Drug: Aronia melanocarpa
Normalized name: ARONIA MELANOCARPA FRUIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aronia melanocarpa juice (AMJ) treatment, 1.17 g/100 mL polyphenols
Study: 32443695
Drug: low‐polyphenol Aronia
Approvals — FDA: no, EMA: no, PMDA: no
Description: low‐polyphenol Aronia melanocarpa juice (dAMJ) treatment, 0.29 g/100 mL polyphenols
Study: 33736920
Drug: GC3110A (quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC3110A (quadrivalent inactivated split-virion influenza vaccine)
Study: 33736920
Drug: Control TIV
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control TIV (inactivated trivalent influenza vaccine)
Study: 32130742
Drug: Treatment 0
Normalized name: Santalia Spot Treatment 0.02 MG/MG Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 0
Study: 34784577
Drug: Enzalutamide 160
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide 160 mg plus androgen deprivation therapy (ADT)
Study: 34784577
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus androgen deprivation therapy (ADT)
Study: 34759176
Drug: Difluprednate 0.05%
Normalized name: DIFLUPREDNATE 0.05% EMULSION,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Difluprednate 0.05% nanoemulsion (DIFL) twice a day
Study: 34759176
Drug: Prednisolone acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone acetate 1% + phenylephrine hydrochloride 0.12% suspension (PRED) 4 times a day
Study: 33258534
Drug: Oral α-lipoic
Normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral α-lipoic acid (ALA) 300 mg daily for 6 months + NB-UVB phototherapy
Study: 36027238
Drug: Caffeinated drink
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeinated drink (3 mg/kg)
Study: 36418946
Drug: 3 ug/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ug/kg intranasal DEX plus 0.2 mg/Kg oral midazolam
Study: 36418946
Drug: 2 ug/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ug/kg intranasal DEX plus 0.2 mg/Kg oral Midazolam
Study: 33420214
Drug: Subcutaneous and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous and intraperitoneal analgesia
Study: 33420214
Drug: Subcutaneous analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous analgesia and intraperitoneal placebo
Study: 33420214
Drug: Subcutaneous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous placebo and intraperitoneal analgesia
Study: 33420214
Drug: Subcutaneous and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous and intraperitoneal placebo
Study: 35396310
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion from 20:00 to 08:00 post-surgery
Study: 33327266
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis with alteplase combined with edaravone
Study: 33327266
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis of alteplase
Study: 35472628
Drug: Continuous IV
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous IV epinephrine infusion (0.00375 mg/kg/min) with placebo IV normal saline (NS) boluses every 4 min
Study: 35472628
Drug: Continuous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous placebo IV NS infusion with IV epinephrine boluses (0.015 mg/kg) every 4 min
Study: 35472628
Drug: Placebo IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV NS for both infusion and boluses
Study: 32329069
Drug: Nomogram integrating
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nomogram integrating epigenetic signature, pathological stage, and postoperative chemotherapy
Study: 32329069
Drug: External validation
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External validation series (combination of GSE17538, GSE33113, GSE37892)
Study: 35784723
Drug: Molnupiravir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molnupiravir (800 mg) plus basic treatment for 5 days (BID)
Study: 35784723
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (only basic treatment)
Study: 39601078
Drug: Molnupiravir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molnupiravir (800 mg)
Study: 32493478
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 400 mg orally daily for 3 days then 200 mg orally daily for an additional 11 days (total 14 days)
Study: 32493478
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 500 mg orally daily for 3 days then 250 mg orally daily for 11 days (total 14 days)
Study: 36032243
Drug: TRI 360TM
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRI 360TM capsules twice a day
Study: 35918281
Drug: Videographic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Videographic and plaque disclosing tablets (PDT)
Study: 35918281
Drug: Plaque disclosing
Normalized name: Plaquenil
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plaque disclosing tablets (PDT)
Study: 33044886
Drug: Plyometric training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plyometric training program (twice/week over three months plus traditional physical rehabilitation)
Study: 33044886
Drug: Traditional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional physical rehabilitation program (45 minutes/session, twice/week for three months)
Study: 36154278
Drug: Gemcitabine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine monotherapy (5 months)
Study: 35322144
Drug: 8 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g/day of gluten for 2 weeks; gluten-tolerating subjects received 16 g/day for 2 weeks and then 32 g/day for a further 2 weeks
Study: 34992749
Drug: Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual Care and Treatment Advice (UC+TA)
Study: 32803439
Drug: Preoperative submucosal
Normalized name: mepivacaine
DrugBank: Mepivacaine (DB00961)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative submucosal corticosteroid injection (n = 16), 8 mg/2 ml dexamethasone 21‐phosphate
Study: 32803439
Drug: Postoperative non‐steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative non‐steroid anti‐inflammatory drug therapy (n = 17), 25 mg dexketoprofen trometamol
Study: 32528568
Drug: Edoxaban 60
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 60 mg once daily (30 mg for creatinine clearance 15-50 mL/min, weight ≤ 60 kg, and/or concomitant use of P-glycoprotein inhibitor)
Study: 33586583
Drug: Curcuma longa
Normalized name: Curcuma Longa
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuma longa L. (500 mg/day with piperine 5 mg)
Study: 32605501
Drug: 1% 5‐fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% 5‐fluorouracil cream
Study: 32605501
Drug: 5% 5‐fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% 5‐fluorouracil cream
Study: 34996820
Drug: Intravenous ketorolac,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac, 10 mg, three times daily for a maximum of 5 days
Study: 32178430
Drug: Agility training
Normalized name: AGIL-FA
DrugBank: AGIL-FA (DB16973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agility training (supervised, group-based, twice a week for one year)
Study: 32737893
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1000 mg intravenous)
Study: 35820112
Drug: Intensive multimodality
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive multimodality therapy including four cycles of chemotherapy followed by involved field radiation therapy (45 Gy) for stage II-III patients.
Study: 35820112
Drug: Intensive multimodality
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive multimodality therapy including four cycles of chemotherapy followed by involved field radiation therapy (45 Gy) for stage IVa patients.
Study: 35820112
Drug: Intensive multimodality
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive multimodality therapy including four cycles of chemotherapy and one cycle of high-dose carboplatin, thiotepa, and etoposide with autologous hematopoietic stem-cell support for stage IVb patients.
Study: 33369684
Drug: General sensorimotor
Approvals — FDA: no, EMA: no, PMDA: no
Description: General sensorimotor training (group therapy)
Study: 34542910
Drug: Self-administered anonymous
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered anonymous questionnaire assessing misconceptions about oral radiology and medicine
Study: 34119566
Drug: Intravenous Clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Clonidine Group (IVCG)
Study: 37517579
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical therapy (BMT)
Study: 33058795
Drug: Cefiderocol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefiderocol (2 g every 8 hours for 7–14 days)
Study: 33058795
Drug: Best available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Best available therapy (pre-specified by the investigator, maximum of three drugs for 7–14 days)
Study: 32075010
Drug: Ketogenic state
Normalized name: CLOZAPINE (GOLDEN STATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketogenic state (βHB ≥0.3 mmol/L)
Study: 34824982
Drug: Internet-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive-behavioral therapy (ICBT) including psychoeducation, cognitive restructuring, attentional training, and exposure.
Study: 36409435
Drug: TAK-931 80
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-931 80 mg tablet
Study: 36409435
Drug: TAK-931 80
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-931 80 mg PIC
Study: 36409435
Drug: TAK-931 50
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-931 50 mg PIC QD
Study: 32091032
Drug: Intralymphatic immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralymphatic immunotherapy (ILIT) with pollen extracts, 3 intralymphatic inguinal injections before the first pollen season.
Study: 32091032
Drug: Intralymphatic immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralymphatic immunotherapy (ILIT) with pollen extracts.
Study: 34694872
Drug: Telacebec (Q203)
Normalized name: Telacebec
DrugBank: Telacebec (DB17754)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telacebec (Q203) 10 to 800 mg